Comparing Fidaxomicin to Other Treatments for Clostridioides difficile Infection
Author Information
Author(s): Li Qinghua, Obi Engels, Marciniak Anne, Newman Rebecca, Whittle Isabelle, Kufakwaro Jason
Primary Institution: Merck & Co., Inc.
Hypothesis
This systematic literature review aimed to explore clinical and economic outcomes associated with fidaxomicin use with or without comparison to vancomycin, metronidazole, or fecal microbiota transplantation (FMT).
Conclusion
Fidaxomicin was clinically effective compared to vancomycin and is often reported as cost-effective, especially in high-risk subpopulations.
Supporting Evidence
- Fidaxomicin showed higher sustained clinical cure rates compared to vancomycin at 30 and 60 days follow-up.
- Lower recurrence rates were reported post-fidaxomicin treatment compared to vancomycin.
- Fidaxomicin was cost-effective in 14 of 21 economic analyses.
Takeaway
Fidaxomicin is a medicine that helps people with a bad stomach infection called CDI, and it works better than some other medicines while also saving money in the long run.
Methodology
The study involved a systematic literature review and meta-analysis of 79 publications, focusing on clinical and economic outcomes of fidaxomicin compared to other treatments.
Potential Biases
Some studies were assessed to be at high-risk of bias, particularly those with open-label designs.
Limitations
The study faced limitations due to heterogeneity in outcome definitions and follow-up periods across included studies.
Participant Demographics
The review included studies with adult patients, with some studies also reporting outcomes in pediatric populations.
Statistical Information
P-Value
0.0007
Confidence Interval
95% CI: 1.8–8.4
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website